![[PDF]](/pb-assets/Icons/adobe-pdf-icon-1498649896243.png){kind=icon}
Abstract
Several recent publications have focused on statistical considerations that arise in multipopulation tailoring clinical trials that evaluate treatment effect in an overall patient population as well as one or more predefined subpopulations. This paper presents a decision-making framework applicable to these trials and evaluates the operating characteristics of this framework versus one based solely on the results of primary hypothesis tests. The operating characteristics are presented as rates of applicable errors, known as influence errors and interaction errors.
References
| 1. |
Simon, R, Maitournam, A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res. 2004;10:6759–6763. Google Scholar | Crossref | Medline | ISI |
| 2. |
Romond, EH, Perez, EA, Bryant, J. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684. Google Scholar | Crossref | Medline | ISI |
| 3. |
Paik, S, Kim, C, Wolmark, N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358:1409–1411. Google Scholar | Crossref | Medline | ISI |
| 4. |
Hayes, DF . Steady progress against HER2-positive breast cancer. N Engl J Med. 2011;365:1336–1338. Google Scholar | Crossref | Medline | ISI |
| 5. |
FDA. Guidance for industry : Enrichment strategies for clinical trials to support approval of human drugs and biological products. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf. Published 2012. Accessed June 27, 2013. Google Scholar |
| 6. |
Mandrekar, SJ, Sargent, DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 2009;27:4027–4034. Google Scholar | Crossref | Medline | ISI |
| 7. |
Millen, BA, Dmitrienko, A, Ruberg, S, Shen, L. A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials. Drug Info J. 2012;46:647–656. Google Scholar | SAGE Journals |
| 8. |
Simon, R, Wang, SJ. Use of genomic signatures in therapeutics development. Pharmacogenomics J. 2006;6:1667–1673. Google Scholar | Crossref | ISI |
| 9. |
Bauer, P . Multiple testing in clinical trials. Stat Med. 1991;10:871–890. Google Scholar | Crossref | Medline | ISI |
| 10. |
Song, Y, Chi, GYH. A method for testing a prespecified subgroup in clinical trials. Stat Med. 2007;26:3535–3549. Google Scholar | Crossref | Medline | ISI |
| 11. |
Jiang, W, Freidlin, B, Simon, R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst. 2007;99:1036–1043. Google Scholar | Crossref | Medline |
| 12. |
Freidlin, B, Simon, R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res. 2005;11:7872–7878. Google Scholar | Crossref | Medline | ISI |
| 13. |
Freidlin, B, Jiang, W, Simon, R. The cross-validated adaptive signature design. Clin Cancer Res. 2010;16:691–698. Google Scholar | Crossref | Medline | ISI |
| 14. |
Cappuzzo, F, Ciuleanu, T, Stelmakh, L; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521–529. Google Scholar | Crossref | Medline | ISI |
| 15. |
[Tarceva US product label] . http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf. Accessed April 6, 2013. Google Scholar |
| 16. |
ClinicalTrials.gov. 17* Poma HBBM . http://clinicaltrials.gov/ct2/show/record/NCT01086748?term=hbbm&rank=1. Accessed June 27, 2013. Google Scholar |
| 17. |
Jia, G, Erickson, RW, Choy, DF. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647–654. Google Scholar | Crossref | Medline | ISI |
| 18. |
[Humira product label] . http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020727s004lbl.pdf. Accessed April 6, 2013. Google Scholar |
| 19. |
[BiDil 2013 US product label] . http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020727s004lbl.pdf. Accessed April 6, 2013 Google Scholar |
| 20. |
[Herceptin US product label] . http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf. Accessed April 6, 2013. Google Scholar |
| 21. |
Rothmann, MD, Zhang, JJ, Lu, L, Fleming, TR. Testing in a prespecified subgroup and the intent-to-treat population. Drug Info J. 2012;46:175–179. Google Scholar | SAGE Journals |
| 22. |
Freidlin, B, McShane, LM, Polley, MY, Korn, EL. Randomized phase II trial designs with biomarkers. J Clin Oncol. 2012;30:3304–3309. Google Scholar | Crossref | Medline | ISI |
| 23. |
Dmitrienko, A, D’Agostino, RB, Huque, MF. Key multiplicity issues in clinical drug development. Stat Med. 2013;32:1079–1111. Google Scholar | Crossref | Medline | ISI |
| 24. |
Zhao, YD, Dmitrienko, A, Tamura, R. Design and analysis considerations in clinical trials with a sensitive subpopulation. Stat Biopharmaceutical Res. 2010;2:72–83. Google Scholar | Crossref | ISI |
| 25. |
Alosh, M, Huque, M. A flexible strategy for testing subgroups and overall population. Stat Med. 2009;28:3–23. Google Scholar | Crossref | Medline | ISI |
| 26. |
Millen, BA, Dmitrienko, A. Chain procedures: a class of flexible closed testing procedures with clinical trial applications. Stat Biopharmaceutical Res. 2011; 3:14–30. Google Scholar | Crossref | ISI |
| 27. |
Dmitrienko, A, Bretz, F, Westfall, PH. Multiple testing methodology. In: Dmitrienko, A, Tamhane, AC, Bretz, F, eds. Multiple Testing Problems in Pharmaceutical Statistics. New York, NY: Chapman and Hall/CRC Press; 2009: 35–98. Google Scholar |
| 28. |
Millen, BA, Dmitrienko, A, Song, G. Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trials. J Biopharm Stat. 2014; 24: 94–109. Google Scholar | Crossref | Medline | ISI |
| 29. |
Alosh, M, Huque, MF. Multiplicity considerations for subgroup analysis subject to consistency constraint. Biometrical J. 2013;55:444–462. Google Scholar | Crossref | Medline | ISI |
| 30. |
Wiens, BL . A fixed sequence Bonferroni procedure for testing multiple endpoints. Pharmaceutical Stat. 2003;2:211–215. Google Scholar | Crossref | ISI |
| 31. |
Wiens, BL, Dmitrienko, A. The fallback procedure for evaluating a single family of hypotheses. J Biopharmaceutical Stat. 2005;15:929–942. Google Scholar | Crossref | Medline | ISI |
